摘要
2016年世界卫生组织将双打击和双表达淋巴瘤重新定义为高级别淋巴瘤,其侵袭性强,预后差,且与c-myc、bcl-2及bcl-6基因的异常表达有关。由于双打击和双表达淋巴瘤在疾病进展及预后方面的差异,R-CHOP对其治疗效果差,而调整后的R-Hyper-CVAD、R-CODOX-M/IVAC及R-EPOCH方案显示了较好的效果,由于其明确的基因异常,靶向治疗可能会成为最有效的治疗方案。文章从其双打击淋巴瘤与双表达淋巴瘤的临床特点、发病机制、诊治等方面进行综述。
In 2016,the World Health Organization redefined double hit lymphoma and double expression lymphoma as high-grade lymphoma,a group lymphoma characterized by aggressive disease and poor prognosis.Double hit lymphoma and double expression lymphoma are related to the abnormal expressions of c-myc,bcl-2 and bcl-6 genes.Because of the differences in disease progression and prognosis of both lymphomas,R-CHOP is less effective in treating them.The adjusted R-Hyper-CVAD,R-CODOX-M/IVAC and R-EPOCH regimens have shown good results,but targeted therapy may be the most effective regimen due to their specific genetic abnormalities.This article will review its clinical characteristics,pathogenesis,diagnosis and treatment of double hit lymphoma and double expression lymphoma.
作者
郭慧玲
吴涛
白海
Guo Huiling;Wu Tao;Bai Hai(Department of Hematology,the 940th Hospital of Joint Logistics Support Force of Chinese PLA,Lanzhou 730050,China)
出处
《白血病．淋巴瘤》
CAS
2020年第5期307-309,共3页
Journal of Leukemia & Lymphoma
基金
甘肃省自然科学基金(145RJZA151)。
